Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.65 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.65 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.60 |
| ▸ | GBA1 | P04062 | 10/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18163271 | 0.98 | HRH4 (0.66) | HRH4HRH3CYP19A1GBA1EPHX2 | |
| SCHEMBL5021143 | 0.98 | HRH4 (0.66) | HRH4HRH3CYP19A1GBA1EPHX2 | |
| SCHEMBL21318217 | 0.98 | HRH4 (0.66) | HRH4HRH3CYP19A1GBA1EPHX2 | |
| SCHEMBL460417 | 0.96 | HRH4 (0.65) | HRH4HRH3CYP19A1GBA1EPHX2 | |
| SCHEMBL24675720 | 0.95 | HRH4 (0.66) | HRH4HRH3CYP19A1GBA1EPHX2 | |
| SCHEMBL19663777 | 0.95 | HRH4 (0.66) | HRH4HRH3CYP19A1GBA1EPHX2 | |
| SCHEMBL21959579 | 0.95 | HRH4 (0.66) | HRH4HRH3CYP19A1GBA1EPHX2 | |
| SCHEMBL15944228 | 0.95 | HRH4 (0.66) | HRH4HRH3CYP19A1GBA1EPHX2 | |
| SCHEMBL11318961 | 0.95 | HRH4 (0.66) | HRH4HRH3CYP19A1GBA1EPHX2 | |
| SCHEMBL19501713 | 0.95 | HRH4 (0.66) | HRH4HRH3CYP19A1GBA1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220324770-A1 | NITRIFICATION INHIBITORS | THE UNIVERSITY OF MELBOURNE (AU) | 2022-10-13 | — | — | US | claimed |
| EP-4025564-A1 | NITRIFICATION INHIBITORS | The University of Melbourne (AU) | 2022-07-13 | — | — | EP | claimed |
| CN-114616227-A | Nitrification inhibitors | 墨尔本大学 | 2022-06-10 | — | — | CN | claimed |
| WO-2021042169-A1 | NITRIFICATION INHIBITORS | THE UNIVERSITY OF MELBOURNE (AU) | 2021-03-11 | — | — | WO | claimed |
| CN-114616227-B | Nitrification inhibitor | 墨尔本大学 | 2025-01-21 | — | — | CN | disclosed |
| US-20220324770-A1 | NITRIFICATION INHIBITORS | THE UNIVERSITY OF MELBOURNE (AU) | 2022-10-13 | — | — | US | disclosed |
| EP-4025564-A1 | NITRIFICATION INHIBITORS | The University of Melbourne (AU) | 2022-07-13 | — | — | EP | disclosed |
| CN-114616227-A | Nitrification inhibitors | 墨尔本大学 | 2022-06-10 | — | — | CN | disclosed |
| WO-2021042169-A1 | NITRIFICATION INHIBITORS | THE UNIVERSITY OF MELBOURNE (AU) | 2021-03-11 | — | — | WO | disclosed |
| WO-2021042169-A1 | NITRIFICATION INHIBITORS | THE UNIVERSITY OF MELBOURNE (AU) | 2021-03-11 | — | — | WO | disclosed |
| US-20190099493-A1 | Targeting Lipids | ARBUTUS BIOPHARMA CORPORATION (CA) | 2019-04-04 | — | — | US | disclosed |
| US-20180085426-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS INC (US) | 2018-03-29 | — | — | US | disclosed |
| WO-2017205786-A1 | CELL PERMEABLE PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
| US-9814777-B2 | Targeting lipids | ARBUTUS BIOPHARMA CORPORATION (CA) | 2017-11-14 | — | — | US | disclosed |
| US-20170114098-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS, INC. | 2017-04-27 | — | — | US | disclosed |
| US-8808694-B2 | Therapeutic peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180085426-A1 | PEPTIDOMIMETIC MACROCYCLES | GLP1R, PROKR1, VIP | HRH4 1851/4885HRH3 2016/4885CYP19A1 1614/4885 |
| US-20170114098-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | NGLY1, BID, DNPEP | HRH4 2561/4885HRH3 2159/4885CYP19A1 2283/4885 |
| US-20190099493-A1 | Targeting Lipids | APOB, LY96, ABHD10 | HRH4 955/4885HRH3 364/4885CYP19A1 4259/4885 |
| US-20220324770-A1 | NITRIFICATION INHIBITORS | NOS1, NOS2, NIT2 | HRH4 1525/4885HRH3 2479/4885CYP19A1 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.